CGBio’s premium aesthetic brand, DCLASSY, has launched official sales in Indonesia, marking the start of its full-scale global market expansion.
CGBio, a Korean regenerative medicine firm focused on bone and spine solutions, said on Thursday that it has begun official sales in Indonesia of DCLASSY CaHA, a premium aesthetic filler based on CaHA (calcium hydroxyapatite) that simultaneously induces skin regeneration and collagen production.
DCLASSY CaHA incorporates the patented Lattice-Pore Formation (LPF) technology, featuring a unique structure with micro-pores arranged in layers within the particles. After injection, once the gel component is absorbed, the CaHA particles slowly degrade, stimulating fibroblasts to produce collagen. This gradual action leads to long-term effects on skin regeneration. The uniform particles, about 30 μm in size, and their smooth surface reduce the risk of post-procedure spread and inflammation, enabling precise design and safe results, CGBio explained.
CGBio Indonesia has been operating specialized training programs for local medical professionals in the lead-up to this launch. Notably, at the “DEEP Master Course” focused on complex treatment strategies, local instructors—who completed trainer courses at the company’s Korean headquarters—conducted lectures and live demonstrations for local medical professionals on protocols such as the Collagen Velvet Protocol (DCLASSY CaHA + Nabota) and the Dual Lift Protocol (DOOTH + DCLASSY HA).
DCLASSY pursues both functionality and sophistication in line with its brand philosophy, combining “Essence (Classic)” and “Elegance (Classy).” The CaHA filler launched in Indonesia offers long-term regenerative capabilities, complementing the DCLASSY HA filler, which is specialized for short-term volume enhancement to support skin volume improvement across different timeframes.
Additionally, DCLASSY recently appointed KLPGA rising star Park Hye-jun as its first sports ambassador and signed an official sponsorship agreement. Through this collaboration, DCLASSY aims to broaden its reach to new customers, including golf fans, and further strengthen its brand presence in the global market, according to CGBio.
“DCLASSY CaHA is a premium solution with a differentiated mechanism of action and clinical efficacy compared to existing fillers,” CGBio CEO Yu Hyun-seung said. “We will continue to invest in local medical professional education and technology dissemination so that Indonesian customers can experience safer and more predictable results.”
CGBio Indonesia plans to further solidify its premium leadership in the CaHA market by expanding its advanced procedural training programs, including the DEEP Master Course, in 2026, following this launch.
